One of the biggest pharma manufacturing opportunities this coming year will be the surging demand for popular weight-loss drugs Ozempic and Wegovy. Obesity drugs are in such high demand in developed markets that there is a shortage of Novo Nordisk’s (Bagsvaerd, Denmark) Wegovy and Ozempic (both semaglutide), and Eli Lilly’s (Indianapolis, IN, US) Mounjaro (tirzepatide) and Trulicity (dulaglutide), all approved or now used off-label to treat obesity. These treatments are proving incredibly successful but insufficient volumes are limiting sales and expansion into new markets. Scaling up to meet manufacturing demand will require considerable time if it is done solely through developing internal capacity, meaning that there is an opportunity for CMOs to secure contracts for high-demand drugs. These medicines reduce appetite and slow down the movement of food in the gut, so patients feel full for longer. By 2030, the anti-obesity medicines market could grow to $30bn for the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), according to GlobalData’s Epidemiology and Market Size database.